Brokerages Set Hims & Hers Health, Inc. (NYSE:HIMS) Target Price at $16.43

Hims & Hers Health, Inc. (NYSE:HIMS) has been assigned a consensus rating of “Moderate Buy” from the sixteen brokerages that are presently covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $17.00.

A number of brokerages have commented on HIMS. Canaccord Genuity Group began coverage on shares of Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price for the company. Piper Sandler boosted their target price on shares of Hims & Hers Health from $11.00 to $13.00 and gave the stock a “neutral” rating in a report on Tuesday, May 7th. Citigroup downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $16.00 to $20.00 in a report on Wednesday, May 22nd. Bank of America boosted their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, Jefferies Financial Group boosted their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 2,503 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $15.65, for a total value of $39,171.95. Following the transaction, the insider now owns 166,866 shares in the company, valued at approximately $2,611,452.90. The sale was disclosed in a filing with the SEC, which is available through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 2,503 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the sale, the insider now owns 166,866 shares in the company, valued at approximately $2,611,452.90. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 962,791 shares of company stock worth $16,930,725. 17.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. lifted its position in shares of Hims & Hers Health by 23.0% during the 4th quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock valued at $163,000 after buying an additional 3,429 shares in the last quarter. Graham Capital Management L.P. raised its stake in Hims & Hers Health by 39.4% in the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock valued at $2,141,000 after purchasing an additional 96,277 shares during the last quarter. Forerunner Ventures Management LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at $86,836,000. Swiss National Bank increased its stake in shares of Hims & Hers Health by 9.2% in the 3rd quarter. Swiss National Bank now owns 309,200 shares of the company’s stock worth $1,945,000 after acquiring an additional 26,100 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after acquiring an additional 428,671 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $20.16 on Monday. Hims & Hers Health has a 1-year low of $5.65 and a 1-year high of $25.74. The company has a 50-day moving average of $17.59 and a 200 day moving average of $13.48. The firm has a market cap of $4.33 billion, a PE ratio of -2,016.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The company had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. During the same period in the prior year, the firm earned ($0.05) earnings per share. The firm’s revenue for the quarter was up 45.8% compared to the same quarter last year. Sell-side analysts anticipate that Hims & Hers Health will post 0.19 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.